Table 2.
Total (n = 10,320) | Nonelderly patients, ≤80 yr (n = 8,645) | Elderly patients, >80 yr (n = 1,675) | P | |||||||
With factor | Without factor | P* | With factor | Without factor | P* | With factor | Without factor | P* | ||
Comorbidities | ||||||||||
Ischemic heart disease, n (%) | 102/730 (14.0) | 387/9,590 (4.0) | <0.001 | 84/550 (15.3) | 309/8,095 (3.8) | 0.001 | 18/180 (10.0) | 78/1,495 (5.2) | 0.016 | 0.119 |
Liver cirrhosis, n (%) | 14/192 (7.3) | 475/10,128 (4.7) | 0.118 | 12/158 (7.6) | 381/8,847 (4.5) | 0.079 | 2/34 (5.9) | 94/1,641 (5.7) | 1.000 | 0.745 |
Hemodialysis, n (%) | 36/155 (23.2) | 453/10,165 (4.5) | <0.001 | 27/115 (23.5) | 366/8,530 (4.3) | <0.001 | 9/40 (22.5) | 87/1,635 (5.3) | <0.001 | 0.921 |
AT therapy, n (%) | 222/1,860 (11.9) | 267/8,460 (3.2) | <0.001 | 177/1,376 (12.9) | 216/7,629 (3.0) | <0.001 | 45/484 (9.3)/ | 51/1,191 (4.3) | <0.001 | 0.063 |
APA, n (%) | 155/1,428 (10.9) | 334/8,892 (3.8) | <0.001 | 122/1,041 (11.7) | 271/7,604 (3.6) | <0.001 | 33/387 (8.5) | 63/1,288 (4.9) | 0.009 | 0.120 |
Aspirin, n (%) | 110/981 (11.2) | 379/9,339 (4.1) | <0.001 | 88/722 (12.2) | 305/7,923 (3.8) | <0.001 | 22/259 (8.5) | 74/1,416 (5.2) | 0.042 | 0.145 |
Cilostazol, n (%) | 20/236 (8.5) | 469/10,084 (4.7) | 0.012 | 13/166 (7.8) | 380/8,479 (4.5) | 0.050 | 7/70 (10.0) | 89/1,605 (5.5) | 0.116 | 0.617 |
Thienopyridine, n (%) | 67/460 (14.6) | 422/9,860 (4.3) | <0.001 | 56/345 (16.2) | 337/8,300 (4.1) | <0.001 | 11/115 (9.6) | 85/1,560 (5.4) | 0.091 | 0.124 |
Anticoagulant drug, n (%) | 111/579 (19.2) | 378/9,741 (3.9) | <0.001 | 91/445 (20.4) | 302/8,200 (3.7) | <0.001 | 20/134 (14.9) | 76/1,541 (4.9) | <0.001 | 0.235 |
Warfarin, n (%) | 68/326 (20.9) | 421/9,994 (4.2) | <0.001 | 52/238 (21.8) | 341/8,407 (4.1) | <0.001 | 16/88 (18.2) | 80/1,587 (5.0) | <0.001 | 0.556 |
DOAC, n (%) | 43/253 (17.0) | 446/10,067 (4.4) | <0.001 | 39/207 (18.8) | 354/8,438 (4.2) | <0.001 | 4/46 (8.7) | 92/1,629 (5.6) | 0.332 | 0.151 |
Interruption of AT agents, n (%) | 175/1,406 (12.4) | 314/8,911 (3.5) | <0.001 | 140/1,034 (13.5) | 253/7,608 (3.3) | <0.001 | 35/372 (9.4) | 61/1,303 (4.7) | 0.001 | 0.065 |
One kind of AT agent, n (%) | 137/1,215 (11.3) | 314/8,911 (3.5) | <0.001 | 108/887 (12.2) | 253/7,608 (3.3) | <0.001 | 29/328 (8.8) | 61/1,303 (4.7) | <0.001 | 0.142 |
Two kinds of AT agent, n (%) | 34/181 (18.8) | 314/8,911 (3.5) | 29/142 (20.4) | 253/7,608 (3.3) | 5/39 (12.8) | 61/1,303 (4.7) | ||||
Three kinds of AT agent, n (%) | 4/10 (40.0) | 314/8,911 (3.5) | 3/5 (60.0) | 253/7,608 (3.3) | 1/5 (20.0)/ | 61/1,303 (4.7) | ||||
Replacement of APAs, n (%) | 14/121 (11.6) | 475/10,198 (4.7) | 0.002 | 10/83 (12.0) | 383/8,561 (4.5) | 0.004 | 4/38 (10.5) | 92/1,637 (5.6) | 0.273 | 0.824 |
Heparin bridging, n (%) | 77/429 (17.9) | 412/9,891 (4.2) | <0.001 | 63/322 (19.6) | 330/8,323 (4.0) | <0.001 | 14/107 (13.1)/ | 82/1,568 (5.2) | 0.004 | 0.200 |
Lesion | ||||||||||
Multiple tumors, n (%) | 83/1,294 (6.4) | 406/9,026 (4.5) | 0.003 | 63/1,053 (6.0) | 330/7,592 (4.3) | 0.022 | 20/241 (8.3) | 76/1,434 (5.3) | 0.072 | 0.218 |
Location in lower third of stomach, n (%) | 270/4,688 (5.8) | 219/5,632 (3.9) | <0.001 | 213/3,860 (5.5) | 180/4,785 (3.8) | <0.001 | 57/828 (6.9) | 39/847 (4.6) | 0.046 | 0.150 |
Undifferentiated type, n (%) | 26/506 (5.1) | 463/9,814 (4.7) | 0.677 | 22/469 (4.7)/ | 371/8,176 (4.5) | 0.820 | 4/37 (10.8) | 92/1,638 (5.6) | 0.158 | 0.132 |
Tumor size (>30 mm), n (%) | 84/1,217 (6.9) | 405/9,103 (4.4) | <0.001 | 66/982 (6.7) | 327/7,663 (4.3) | 0.001 | 18/235 (7.7) | 78/1,440 (5.4) | 0.173 | 0.635 |
Invasion to SM2, n (%) | 39/655 (6.0) | 450/9,664 (4.7) | 0.125 | 30/535 (5.6) | 363/8,109 (4.5) | 0.237 | 9/120 (7.5)/ | 87/1,555 (5.6) | 0.411 | 0.458 |
Ulceration (scar), n (%) | 51/977 (5.2) | 437/9,320 (4.7) | 0.479 | 39/813 (4.8) | 353/7,811 (4.5) | 0.723 | 12/164 (7.3) | 84/1,508 (5.6) | 0.375 | 0.212 |
Procedure | ||||||||||
Procedure time >120 min, n (%) | 112/1,886 (5.9) | 375/8,411 (4.5) | 0.007 | 90/1,570 (5.7) | 302/7,061 (4.3) | 0.016 | 22/316 (7.0) | 73/1,350 (5.4) | 0.282 | 0.428 |
En block resection, n (%) | 486/10,259 (4.7) | 3/61 (4.9) | 0.765 | 391/8,597 (4.5) | 2/48 (4.2) | 0.899 | 95/1,662 (5.7) | 1/13 (7.7) | 0.537 | 0.051 |
Second-look endoscopy, n (%) | 361/7,384 (4.9) | 128/2,936 (4.4) | 0.259 | 292/6,128 (4.8) | 101/2,517 (4.0) | 0.139 | 69/1,256 (5.5) | 27/419 (6.4) | 0.468 | 0.300 |
Perforation, n (%) | 5/154 (3.2) | 483/10,149 (4.8) | 0.664 | 4/127 (3.1) | 389/8,503 (4.6) | 0.522 | 1/27 (3.7)/ | 94/1,646 (5.7) | 0.192 | 0.887 |
Transfusion, n (%) | 138/143 (96.5) | 350/10,176 (3.4) | <0.001 | 107/111 (96.4) | 285/8,533 (3.3) | <0.001 | 31/32 (96.9) | 65/1,643 (4.0) | <0.001 | 0.986 |
Surgery, n (%) | 0 (0) | 489/10,320 (4.7) | — | 0 (0) | 393/8,645 (4.5) | — | 0 (0) | 96/1,675 (5.7) | — | — |
Death, n (%) | 0 (0) | 489/10,320 (4.7) | — | 0 (0) | 393/8,645 (4.5) | — | 0 (0) | 96/1,675 (5.7) | — | — |
P: comparison of the rate of patients with the factor between nonelderly patients and elderly patients.
P*: comparison of the rate between patients with and without the factor.
APA, antiplatelet agent; AT, antithrombotic; DOAC, direct oral anticoagulant; ESD, endoscopic submucosal dissection; H2RA, histamine 2 receptor antagonist; P-CAB, potassium-competitive acid blocker; PPI, proton pump inhibitor; SM2, submucosal invasion ≥500 μm from the muscularis mucosa.